keyword
MENU ▼
Read by QxMD icon Read
search

Nhl

keyword
https://www.readbyqxmd.com/read/27918211/new-targeted-therapies-for-malignant-lymphoma-based-on-molecular-heterogeneity
#1
Heike Horn, Annette M Staiger, German Ott
Owing to tremendous advances in the understanding of mechanisms involved in the pathogenesis of malignant tumors an emerging field of novel targeted drugs has evolved within the last decade. This is of particular interest also for malignant lymphomas, constituting a heterogeneous tumor category with substantial variation in clinical outcome, ranging from indolent forms that do not require treatment over years to aggressive cases for which an immediate treatment is mandatory. The elucidation of different molecular strategies adopted by malignant cells has led to a profound profiling of tumor-specific features and consequently resulted in the development of new targeted therapies...
December 5, 2016: Expert Review of Hematology
https://www.readbyqxmd.com/read/27913533/non-hodgkin-lymphoma-across-the-pediatric-and-adolescent-and-young-adult-age-spectrum
#2
John T Sandlund, Mike G Martin
The non-Hodgkin lymphomas (NHLs) occurring in children and adolescents and young adults (AYA) are characterized by various age-related differences in tumor biology and survival. Children generally present with high-grade lymphomas, such as Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma, whereas low-grade histologic subtypes, such as follicular lymphoma, occur more frequently with increasing age. Treatment outcome for children with NHL is generally superior to that observed in adults...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27913504/primary-central-nervous-system-lymphoma
#3
Tracy T Batchelor
Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma (NHL) confined to the brain, leptomeninges, eyes, or spinal cord. The majority of PCNSL cases occur in the immunocompetent host, the focus of this review. The prognosis of PCNSL is inferior to that of other NHL subtypes including other organ-specific subtypes of extranodal NHL. The 5- and 10-year survival proportions for PCNSL are 29.3% and 21.6%, respectively. The diagnosis and management of PCNSL differs from that of other primary brain cancers and NHL in other parts of the body...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27910030/recurrent-cytogenetic-abnormalities-in-non-hodgkin-s-lymphoma-and-chronic-lymphocytic-leukemia
#4
Edmond S K Ma
Characteristic chromosomal translocations are found to be associated with subtypes of B-cell non-Hodgkin lymphoma (NHL), for example t(8;14)(q24;q32) and Burkitt lymphoma, t(14;18)(q32;q21) and follicular lymphoma, and t(11;14)(q13;q32) in mantle cell lymphoma. Only few recurrent cytogenetic aberrations have been identified in the T-cell NHL and the best known is the ALK gene translocation t(2;5)(p23;q35) in anaplastic large cell lymphoma. Since lymph node or other tissue is seldom submitted for conventional cytogenetics study, alternative approaches for translocation detection are polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH)...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27905485/b-and-t-lymphocyte-number-and-function-in-hiv-hiv-lymphoma-patients-treated-with-high-dose-chemotherapy-and-autologous-bone-marrow-transplantation
#5
Diego Bertoli, Alessandro Re, Marco Chiarini, Alessandra Sottini, Federico Serana, Viviana Giustini, Aldo M Roccaro, Chiara Cattaneo, Luigi Caimi, Giuseppe Rossi, Luisa Imberti
Combination of anti-retroviral therapy, high-dose chemotherapy (HCT) and autologous stem cell transplantation (ASCT) has led to an improved survival of HIV(+) non-Hodgkin lymphoma (NHL) patients. We compared T- and B-cell subset recovery and related capability to respond to in-vitro stimulation, as well as T-cell repertoire modifications of HIV(+) and HIV(-) NHL patients undergoing HCT and ASCT as first-line consolidation or salvage treatment, using sequential blood samples obtained before and at 3, 6, 12 and 24 months after ASCT...
December 1, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27900638/bendamustine-plus-rituximab-for-previously-untreated-patients-with-indolent-b-cell-non-hodgkin-lymphoma-or-mantle-cell-lymphoma-a-multicenter-phase-ii-clinical-trial-in-japan
#6
Michinori Ogura, Kenichi Ishizawa, Dai Maruyama, Naokuni Uike, Kiyoshi Ando, Koji Izutsu, Yasuhito Terui, Yoshitaka Imaizumi, Kunihiro Tsukasaki, Kenshi Suzuki, Tohru Izumi, Kensuke Usuki, Tomohiro Kinoshita, Masafumi Taniwaki, Nobuhiko Uoshima, Junji Suzumiya, Mitsutoshi Kurosawa, Hirokazu Nagai, Toshiki Uchida, Noriko Fukuhara, Ilseung Choi, Ken Ohmachi, Go Yamamoto, Kensei Tobinai
A Phase II, multicenter clinical trial of bendamustine plus rituximab (BR) regimen was conducted in previously untreated patients with high-tumor-burden indolent B-cell non-Hodgkin lymphoma (B-NHL) and previously untreated elderly patients with mantle cell lymphoma (MCL) in Japan. Bendamustine 90 mg/m(2)/day on days 1 and 2, as well as rituximab 375 mg/m(2) on day 1 were administered intravenously up to six cycles. The primary endpoint was the complete response (CR) rate as assessed by the International Workshop Response Criteria (1999)...
November 29, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27897125/a-comparison-of-thresholds-of-auditory-steady-state-response-and-auditory-brainstem-response-in-healthy-term-babies
#7
Onur Çelik, Görkem Eskiizmir, Uzdan Uz
OBJECTIVE: The goal of this study was to assess the effectiveness of auditory steady-state response (ASSR), determine the cut-off values for each frequency, and detect the best correlated frequencies when compared with the auditory brainstem response (ABR) thresholds in term babies under the age of 12 months. MATERIALS AND METHODS: In total, 88 term babies with a mean age of 2.98 (1-11) months (174 ears) underwent ASSR and ABR tests. The ASSR thresholds for the frequencies of 500, 1000, 2000, and 4000 Hz were compared with the hearing level of the ABR thresholds...
November 28, 2016: Journal of International Advanced Otology
https://www.readbyqxmd.com/read/27896915/evaluation-of-maternal-and-perinatal-characteristics-on-childhood-lymphoma-risk-a-population-based-case-control-study
#8
Erin C Peckham-Gregory, Heather E Danysh, Austin L Brown, Olive Eckstein, Amanda Grimes, Rikhia Chakraborty, Joseph Lubega, Kenneth L McClain, Carl E Allen, Michael E Scheurer, Philip J Lupo
BACKGROUND: Lymphoma is one of the most common pediatric malignancies; however, there are few well-established risk factors. Therefore, we investigated if maternal and perinatal characteristics influenced the risk of childhood lymphoma. PROCEDURE: Information on cases (n = 374) diagnosed with lymphoma and born in Texas for the period 1995-2011 was obtained from the Texas Cancer Registry. Birth certificate controls were randomly selected at a ratio of 10 controls per 1 case for the same period of 1995-2011...
November 28, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27896671/a-comparison-of-the-brainstem-auditory-evoked-response-in-healthy-ears-of-unilaterally-deaf-dogs-and-bilaterally-hearing-dogs
#9
M Plonek, J Nicpoń, K Kubiak, M Wrzosek
AIMS: Auditory plasticity in response to unilateral deafness has been reported in various animal species. Subcortical changes occurring in unilaterally deaf young dogs using the brainstem auditory evoked response have not been evaluated yet. The aim of this study was to assess the brainstem auditory evoked response findings in dogs with unilateral hearing loss, and compare them with recordings obtained from healthy dogs. METHODS: Brainstem auditory evoked responses (amplitudes and latencies of waves I, II, III, V, the V/I wave amplitude ratio, wave I-V, I-III and III-V interpeak intervals) were studied retrospectively in forty-six privately owned dogs, which were either unilaterally deaf or had bilateral hearing...
November 29, 2016: Veterinary Research Communications
https://www.readbyqxmd.com/read/27892948/long-term-outcomes-after-thiotepa-based-high-dose-therapy-hdt-and-autologous-hematopoietic-cell-transplantation-auto-hct-in-non-hodgkin-lymphoma-nhl
#10
N Shah, S Rauenzahn, L Veltri, S Wen, M Craig, M Hamadani, A S Kanate, A Cumpston
No abstract text is available yet for this article.
November 28, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27890995/endotracheobronchial-lymphoma-two-unusual-case-reports-and-review-of-article
#11
Trilok Chand, Avdhesh Bansal, Harsh Dua, Kapil Sharma
The tracheobronchial origin of non-Hodgkin's lymphoma (NHL) is a very rare presentation, and there are only a few case reports of primary tracheal or endobronchial NHL. We have two cases of primary tracheobronchial NHL; one case was incidentally diagnosed as anaplastic large cell lymphoma of endobronchial origin when a comprehensive workup and surgery were carried out for an endobronchial aspergilloma which was actually sitting on top of lymphoma. The second patient was a case of myelodysplastic syndrome who presented with acute respiratory distress; on thorough workup, he was found to have endotracheal B-cell lymphoma...
November 2016: Lung India: Official Organ of Indian Chest Society
https://www.readbyqxmd.com/read/27878966/risk-adapted-stratification-for-optimally-intensive-treatment-assignment-of-pediatric-patients-with-non-hodgkin-lymphoma-is-an-effective-strategy-in-developing-countries
#12
Asim F Belgaumi, Mohammed Anas, Khawar S Siddiqui, Mohammed F Akhter, Amani Al-Kofide
BACKGROUND: Pediatric patients with non-Hodgkin lymphoma (NHL) in developing countries (DCs) present with greater tumor load even at lower stages and with comorbidities that impact therapy delivery. This causes toxic mortality with "standard" intensive protocols or recurrences with "gentler" treatment. OBJECTIVES: We developed and evaluated a risk stratification schema that guides intensity of therapy. DESIGN/METHODS: Sixty-nine patients were prospectively assigned to five risk groups (A-E; n = 6, 15, 16, 15, and 17) following staging and treated with protocols of risk-stratified intensity...
November 23, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27876058/a-novel-non-hodgkin-lymphoma-murine-model-closer-to-the-standard-clinical-scenario
#13
Thais Bascuas, María Moreno, Amy Mónaco, Laura Reyes, Andrea Paolino, Patricia Oliver, María G Kramer, Henry Engler, José P Pacheco, Sofía Grille, José A Chabalgoity
BACKGROUND: Non-Hodgkin lymphomas (NHL) are the most frequent hemato-oncological malignancies. Despite recent major advances in treatment, a substantial proportion of patients relapses highlighting the need for new therapeutic modalities. Promissory results obtained in pre-clinical studies are usually not translated when moving into clinical trials. Pre-clinical studies are mainly conducted in animals with high tumor burden; instead patients undergo chemotherapy as first line of treatment and most likely are under remission when immunotherapies are applied...
November 22, 2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/27875673/recent-advances-in-engineered-t-cell-therapies-targeting-b-cell-malignancies
#14
Nathan Singh
Immunotherapy using engineered autologous T cells has been attempted for decades, but clinical trials have only recently demonstrated efficacy. The combination of enhanced manufacturing techniques, highly efficient engineering, appropriate target selection and synthetic receptors with potent T cell activating domains has led to the development of highly-active cellular therapy products. B-cell malignancies have served as the paradigmatic diseases to initially evaluate and subsequently hone engineered T cells targeting cancer...
October 2016: Discovery Medicine
https://www.readbyqxmd.com/read/27871006/evaluating-the-use-of-friend-or-family-controls-in-epidemiologic-case-control-studies
#15
Charlie Zhong, Myles Cockburn, Wendy Cozen, Jenna Voutsinas, James V Lacey, Jianning Luo, Jane Sullivan-Halley, Leslie Bernstein, Sophia S Wang
BACKGROUND: Traditional methodologies for identifying and recruiting controls in epidemiologic case-control studies, such as random digit dialing or neighborhood walk, suffer from declining response rates. Here, we revisit the feasibility and comparability of using alternative sources of controls, specifically friend and family controls. METHODS: We recruited from a recently completed case-control study of non-Hodgkin lymphoma (NHL) among women in Los Angeles County where controls from the parent study were ascertained by neighborhood walk...
November 18, 2016: Cancer Epidemiology
https://www.readbyqxmd.com/read/27869173/pterostilbene-induces-apoptosis-and-cell-cycle-arrest-in-diffuse-large-b-cell-lymphoma-cells
#16
Yuanyuan Kong, Gege Chen, Zhijian Xu, Guang Yang, Bo Li, Xiaosong Wu, Wenqin Xiao, Bingqian Xie, Liangning Hu, Xi Sun, Gaomei Chang, Minjie Gao, Lu Gao, Bojie Dai, Yi Tao, Weiliang Zhu, Jumei Shi
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). Pterostilbene, a natural dimethylated analog of resveratrol, has been shown to possess diverse pharmacological activities, including anti-inflammatory, antioxidant and anticancer properties. However, to the best of our knowledge, there has been no study of the effects of pterostilbene upon hematological malignancies. Herein, we report the antitumor activity and mechanism of pterostilbene against DLBCL cells both in vitro and in vivo...
November 21, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27861844/periodontal-disease-and-risk-of-non-hodgkin-lymphoma-in-the-health-professionals-follow-up-study
#17
Kimberly A Bertrand, Janki Shingala, Andrew Evens, Brenda M Birmann, Edward Giovannucci, Dominique S Michaud
Periodontal disease is a chronic inflammatory condition that has been associated with chronic diseases, including cancer. In an earlier prospective cohort analysis within the Health Professionals Follow-Up Study (HPFS), we observed a 31% higher risk of non-Hodgkin lymphoma (NHL) among participants with severe periodontal disease at baseline. Here, we extend the study with an additional 8 years of follow-up, and conduct analyses with updated periodontal disease status and NHL subtypes. The HPFS is an ongoing prospective cohort study of 51,529 men in the USA Between baseline in 1986 and 2012, 875 cases of NHL were diagnosed, including 290 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 85 diffuse large B-cell lymphomas and 91 follicular lymphomas...
November 15, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27860222/late-outcomes-of-adult-survivors-of-childhood-non-hodgkin-lymphoma-a-report-from-the-st-jude-lifetime-cohort-study
#18
Matthew J Ehrhardt, John T Sandlund, Nan Zhang, Wei Liu, Kirsten K Ness, Nickhill Bhakta, Wassim Chemaitilly, Kevin R Krull, Tara M Brinkman, Deborah B Crom, Larry Kun, Sue C Kaste, Gregory T Armstrong, Daniel M Green, Kumar Srivastava, Leslie L Robison, Melissa M Hudson, Daniel A Mulrooney
BACKGROUND: Survivors of childhood non-Hodgkin lymphoma (NHL) are at increased risk for chronic health conditions. The objective of this study was to characterize health conditions, neurocognitive function, and physical performance among a clinically evaluated cohort of 200 childhood NHL survivors. METHOD: Chronic health and neurocognitive conditions were graded as per a modified version of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and impaired physical function defined as performance < 10th percentile of normative data...
November 15, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27859472/effect-of-ketoconazole-a-strong-cyp3a-inhibitor-on-the-pharmacokinetics-of-venetoclax-a-bcl-2-inhibitor-in-patients-with-non-hodgkin-lymphoma
#19
Suresh K Agarwal, Ahmed Hamed Salem, Alexey V Danilov, Beibei Hu, Soham Puvvada, Martin Gutierrez, David Chien, Lionel D Lewis, Shekman L Wong
AIM: To examine the effect of a strong CYP3A inhibitor, ketoconazole, on the pharmacokinetics, safety, and tolerability of venetoclax. METHODS: Twelve patients with Non-Hodgkin lymphoma (NHL) were enrolled in this Phase 1, open-label, fixed-sequence study. Patients received a single 50 mg dose of venetoclax orally on Day 1 and Day 8, and a 400 mg once daily dose of ketoconazole on Days 5 through 11. Blood samples were collected predose and up to 96 hours after each venetoclax dose on Day 1 and Day 8...
November 2, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27858330/primary-mediastinal-large-b-cell-lymphoma-in-japanese-children-and-adolescents
#20
Tomoo Osumi, Fumiko Tanaka, Tetsuya Mori, Reiji Fukano, Masahito Tsurusawa, Koichi Oshima, Atsuko Nakazawa, Ryoji Kobayashi
This is the first case series to describe primary mediastinal large B-cell lymphoma (PMLBL) patients in children and adolescents in Asia. We retrospectively identified 17 PMLBL patients diagnosed between 1991 and 2014; in seven of these cases, the diagnosis was confirmed by central review, representing 1.0% of all NHL and 2.2% of all B-NHL cases registered. All patients were teenagers, including seven adolescents, with a median age of 14 years (range 12-18 years). Ten patients were male, and seven were female...
November 17, 2016: International Journal of Hematology
keyword
keyword
17878
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"